Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Polyphor AG Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced HER2 Negative Breast Cancer

06/28/2021 | 01:00am EDT

Polyphor AG announced that its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2 negative, locally recurrent or metastatic breast cancer, did not meet its co-primary endpoint. At the primary analysis, balixafortide plus eribulin showed no improvement in the objective response rate (ORR) compared with eribulin alone (13.0% versus 13.7%; p=1.00) in the third line and later population (n=330 patients) followed for a minimum of 6 months. The clinical benefit rate, a key secondary endpoint indicating a stable disease or any confirmed response for a duration of at least 6 months as assessed by the IRC (independent radiological committee) was observed in 16.7% of patients in the balixafortide plus eribulin arm and 19.6% in the eribulin alone arm. The study confirmed the positive safety and tolerability profile of balixafortide in line with the previously reported Phase Ib study. Polyphor will continue to analyze the data, review with the experts and will decide about the future of the study in mid-July. The board of directors is undergoing a strategic assessment and will consider a full range of options regarding the future of the company and will provide an update not later than end of July.


ę S&P Capital IQ 2021
All news about POLYPHOR AG
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepava..
DJ
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
08/03EQS-ADHOC : Polyphor provides final update on the Phase III FORTRESS study of balixafortid..
DJ
08/03Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Pati..
CI
07/30POLYPHOR : To Layoff 20 Staff After Negative Results From Breast Cancer Treatment Study
MT
More news
Financials
Sales 2021 1,00 M 1,08 M 1,08 M
Net income 2021 -41,4 M -44,9 M -44,9 M
Net Debt 2021 76,8 M 83,3 M 83,3 M
P/E ratio 2021 -0,52x
Yield 2021 -
Capitalization 23,1 M 25,0 M 25,0 M
EV / Sales 2021 99,9x
EV / Sales 2022 5,71x
Nbr of Employees 52
Free-Float 81,5%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 1,96 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-75.95%25
CSL LIMITED10.32%102 198
WUXI BIOLOGICS (CAYMAN) INC.18.19%66 153
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 008
BIOGEN INC.20.70%44 045
ALEXION PHARMACEUTICALS, INC.0.00%40 336